The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy.
Rosalie C OeyLennart E M BuckNicole S ErlerHenk R van BuurenRobert A de ManPublished in: Therapeutic advances in gastroenterology (2019)
The addition of rifaximin-α to lactulose treatment was associated with a significant reduction in the number and length of HE-related hospitalizations for overt HE. Rifaximin-α treatment was well tolerated.
Keyphrases